Published in Ann Surg on March 01, 2013
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med (2015) 1.00
Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther (2013) 0.91
Wnt blockers inhibit the proliferation of lung cancer stem cells. Drug Des Devel Ther (2015) 0.85
The roles of Notch3 on the cell proliferation and apoptosis induced by CHIR99021 in NSCLC cell lines: a functional link between Wnt and Notch signaling pathways. PLoS One (2013) 0.82
Stemness and plasticity of lung cancer cells: paving the road for better therapy. Onco Targets Ther (2014) 0.80
Tumor suppressor function of ezrin-radixin-moesin-binding phosphoprotein-50 through β-catenin/E-cadherin pathway in human hepatocellular cancer. World J Gastroenterol (2013) 0.77
The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer. BMC Cancer (2016) 0.75
The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines. Cancer Cell Int (2017) 0.75
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Wnt signaling and cancer. Genes Dev (2000) 18.53
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell (2002) 13.92
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg (1995) 9.51
Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol (1998) 9.24
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science (2000) 7.25
Multidisciplinary management of lung cancer. N Engl J Med (2004) 7.13
Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov (2006) 5.29
Lung cancer. Lancet (2000) 3.93
The oncogenic activation of beta-catenin. Curr Opin Genet Dev (1999) 3.87
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg (1995) 3.31
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res (1998) 2.42
Beta-catenin mutations in human prostate cancer. Cancer Res (1998) 2.37
The ras oncogenes in human lung cancer. Am Rev Respir Dis (1990) 2.31
Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res (1998) 2.27
Epithelial-mesenchymal interactions in the developing lung. Annu Rev Physiol (2004) 2.08
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res (1998) 2.01
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst (2001) 1.72
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 1.67
Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res (2000) 1.55
Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55
Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst (1999) 1.50
Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res (1999) 1.47
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol (1999) 1.46
Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene (2009) 1.40
Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene (1998) 1.36
Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer (2001) 1.32
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer (1998) 1.19
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene (2001) 1.18
Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer (2008) 1.18
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene (1993) 1.14
New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther (2009) 1.07
Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol (2009) 1.06
Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung Cancer (2008) 1.04
Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg (2007) 1.03
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest (2005) 1.01
The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol (1998) 0.99
Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer (2002) 0.94
Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? Eur J Cancer (2005) 0.92
Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg (2003) 0.92
Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med (1998) 0.92
Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer. Thorac Cardiovasc Surg (2009) 0.84
K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch (1994) 0.82
Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park) (2005) 0.76
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg (2008) 4.25
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med (2010) 3.91
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20
MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg (2007) 2.85
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg (2004) 2.53
ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol (2004) 2.50
Efficacy of an evidence-based clinical decision support in primary care practices: a randomized clinical trial. JAMA Intern Med (2013) 2.44
Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest (2007) 2.43
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest (2008) 2.39
Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res (2005) 2.32
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev (2010) 2.28
Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol (2003) 2.16
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J (2002) 2.07
Sonographic diagnosis of true neurogenic thoracic outlet syndrome. Neurology (2013) 1.97
Impact of positive and negative beliefs about inhaled corticosteroids on adherence in inner-city asthmatic patients. Ann Allergy Asthma Immunol (2009) 1.92
Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance. J Thorac Cardiovasc Surg (2008) 1.88
Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. Eur J Cardiothorac Surg (2013) 1.86
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 1.86
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.69
A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol (2003) 1.67
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.62
Comprehensive management of symptomatic and aggressive vertebral hemangiomas. Neurosurg Clin N Am (2008) 1.57
Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg (2003) 1.56
Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma. Prim Care Respir J (2011) 1.55
Predictors of major morbidity and mortality after pneumonectomy utilizing the Society for Thoracic Surgeons General Thoracic Surgery Database. Ann Thorac Surg (2010) 1.54
Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer (2008) 1.49
P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J (2002) 1.48
Video-assisted thoracoscopic lobectomy: state of the art and future directions. Ann Thorac Surg (2008) 1.48
Barriers to adherence to COPD guidelines among primary care providers. Respir Med (2011) 1.47
Validation of a model to predict perioperative mortality from lung cancer resection in the elderly. Am J Respir Crit Care Med (2008) 1.47
Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol (2009) 1.46
BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol (2004) 1.44
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J (2003) 1.44
Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J Cell Biol (2009) 1.44
Airway stents. Ann Thorac Surg (2008) 1.43
A model to create an efficient and equitable admission policy for patients arriving to the cardiothoracic ICU. Crit Care Med (2013) 1.42
Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol (2005) 1.41
Current treatment strategies and outcomes in the management of symptomatic vertebral hemangiomas. Neurosurgery (2006) 1.40
The mechanism of endogenous receptor activation functionally distinguishes prototype canonical and noncanonical Wnts. Mol Cell Biol (2005) 1.39
RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. Curr Biol (2006) 1.37
Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy for patients with small stage I lung cancer. J Thorac Cardiovasc Surg (2009) 1.35
Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg (2011) 1.34
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther (2002) 1.33
Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study. J Altern Complement Med (2009) 1.30
Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer (2012) 1.30
Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res (2008) 1.26
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol (2002) 1.25
P53 promoter selection: choosing between life and death. Cell Cycle (2007) 1.25
CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent manner. EMBO J (2007) 1.25
Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J Cell Sci (2010) 1.24
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell (2011) 1.22
Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg (2007) 1.20
Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys (2008) 1.19
Concern DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J Biol Chem (2011) 1.18
Patients rate physician communication about lung cancer. Cancer (2011) 1.16
Troubleshooting video-assisted thoracic surgery lobectomy. Ann Thorac Surg (2005) 1.14
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol (2005) 1.13
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg (2012) 1.11
Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem (2002) 1.11
Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int (2011) 1.08
p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J Immunol (2011) 1.08
Emphysema scores predict death from COPD and lung cancer. Chest (2011) 1.07
Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res (2005) 1.07
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther (2002) 1.06
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Cancer (2011) 1.06
Abelson family kinases regulate Frizzled planar cell polarity signaling via Dsh phosphorylation. Genes Dev (2010) 1.06
Evidence against a role for SV40 in human mesothelioma. Cancer Res (2005) 1.05
Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc Natl Acad Sci U S A (2011) 1.04
Racial disparities in esophageal cancer treatment and outcomes. Ann Surg Oncol (2007) 1.04
Quality and access to care among a cohort of inner-city adults with asthma: who gets guideline concordant care? Chest (2005) 1.04
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer (2012) 1.04
Use of herbal remedies and adherence to inhaled corticosteroids among inner-city asthmatic patients. Ann Allergy Asthma Immunol (2010) 1.02
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med (2012) 1.02